BIOLOGICAL CONTAINMENT OF LIVE BACTERIAL VACCINES

Information

  • Research Project
  • 2864002
  • ApplicationId
    2864002
  • Core Project Number
    R42AI038599
  • Full Project Number
    2R42AI038599-02
  • Serial Number
    38599
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1995 - 30 years ago
  • Project End Date
    8/31/2001 - 24 years ago
  • Program Officer Name
  • Budget Start Date
    9/15/1999 - 26 years ago
  • Budget End Date
    8/31/2000 - 25 years ago
  • Fiscal Year
    1999
  • Support Year
    2
  • Suffix
  • Award Notice Date
    9/8/1999 - 26 years ago
Organizations

BIOLOGICAL CONTAINMENT OF LIVE BACTERIAL VACCINES

DESCRIPTION: (Adapted from the Applicant's Abstract) The long-term goals of the proposed research are directed at developing safe and efficacious recombinant avirulent Salmonella vaccines for oral administration to protect humans against bacterial, viral and mycotic pathogens, especially those that colonize on or invade into mucosal surfaces. Vaccines are also being constructed and evaluated (i) to immunize farm animals, especially poultry to prevent infection and colonization by human enteropathogens that are transmitted through the food chain to humans, (ii) to express hormones and or gamete-specific antigens to induce immune responses leading to sterilization or to block fertilization, (iii) to induce immune responses to tumor antigens or to kill tumor cells, and (iv) to augment and/or modulate the immune response expressed foreign antigens by co-expression of cytokines. Oral immunization with live Salmonella vaccines gives rise to the potential for fecal shedding with release to the environment of bacteria which could lead to immunization of individuals who did not elect to be vaccinated. There is also the possibility that farm animals that were sent to market too soon after immunization with these vaccines might lead to transmission of the vaccine strain through the food chain to humans. The objectives of the research proposed for the Phase II study are to continue to construct and evaluate strains with containment systems that lead to lysis or death within the immunized animal and that are unable to survive and proliferate in the environment. The strains will be tested for containment, avirulence and immunogenic attributes in vitro and after excretion. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R42
  • Administering IC
    AI
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
  • Organization Name
    MEGAN HEALTH, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    ST. LOUIS
  • Organization State
    MO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    63110
  • Organization District
    UNITED STATES